

**Supplementary table 2. (2<sup>o</sup> Sensitivity analysis). Demographic and clinical characteristics of patients with inflammatory arthritis who discontinued therapy according to clinical remission vs patients who continue**

		Total	Disc. owing to rem	No disc. owing to rem	P value
N		1748	80	1668	
Median duration of follow-up (years) (IQR:p25-p75)		3,00 (1.00- 6.90)	5.57 (3.73-8.89)	2.70 (1.00-6.60)	<0.001
Age, years mean (SD)		52.7 (13.8)	49.9 (15.1)	52.8 (13.8)	0.07
Female sex, n (%)		1105 (63.2)	43.0 (53.8)	1062 (63.7)	0.072
Age at diagnosis, mean (SD)		43.4 (14.1)	43.3 (14.4)	43.4 (14.1)	0.977
Disease duration, years, mean (SD)		8.2 (8.3)	6.6 (4.7)	8.3 (8.3)	0.005
Smoker, n (%)	Never	1155 (66.1)	68 (85.0)	1087 (65.2)	0.003
	Current	368 (21.1)	9 (11.3)	359 (21.5)	
	Previous	175 (10.0)	2 (2.5)	173 (10.4)	
Charlson Comorbidity Index, mean (SD)		2.2 (1.5)	1.8 (1.5)	2.2 (1.5)	0.043
Previous biologic DMARD, n (%)	First-line	1041 (59.6)	47.0 (58.8)	994 (59.6)	0.881
	Second-line	707 (40.4)	33.0 (41.3)	674 (40.4)	
Concomitant DMARD	MTX	695 (61.3)	25.0 (44.6)	670 (62.2)	0.008
	LFN	330 (34.3)	11.0 (22.0)	319 (35.0)	0.059
	SSZ	96 (11.5)	5.0 (10.0)	91 (11.6)	0.734
Time on treatment with the previous biologic agent, mean (SD)		26.2 (37.4)	50.2 (40.0)	25.0 (36.9)	<0.001
Biologic discontinued, n (%)	TNF-i	1270 (72.7)	72 (90.0)	1198 (71.8)	0.088
	IL6-i	124 (7.1)	3 (3.8)	121 (7.3)	
	CD20-i	182 (10.4)	2 (2.5)	180 (10.8)	
	JAK-i	39 (2.2)	0 (0)	39 (2.3)	
	IL17-i	36 (2.1)	0 (0)	36 (2.2)	
	IL12-23-i	6 (0.3)	0 (0)	6 (0.4)	
	Apremilast	24 (1.4)	0 (0)	24 (1.4)	
	Abatacept	62 (3.5)	3 (3.8)	59 (3.5)	
RF-positive, n (%)		473 (27.1)	9 (11.3)	464 (27.8)	0.043
ACPA-positive, n (%)		437 (41.9)	3 (8.6)	434 (43.1)	<0.001
HLA-B27-positive, n (%)		375 (21.5)	18 (22.5)	357 (21.4)	0.030

Moderate-high disease activity at initiation of biologics *	310 (23.3)	9 (17.0)	301 (23.6)	0.256
---	------------	----------	------------	-------

Footnote to table 1. Data are shown as mean (SD), except for categorical variables, which are shown as total number (percentage); Disc: Discontinuation; Rem: Remission; MTX: methotrexate, LFN: leflunomide; SSZ: sulfasalazine; i: inhibitor; RF: rheumatoid factor; ACPA: anti-citrullinated peptide antibody.

\*Moderate-high disease activity was defined as DAS28  $\geq 3.2$  or BASDAI  $\geq 4$ , depending on the disease.